Efficacy and Toxicity of Paclitaxel (Taxol) for the Treatment of Canine Malignant Tumors

Poirier, Valérie J.; Hershey, Alexander; Burgess, Kristine; Phillips, Brenda; Turek, Michelle; Forrest, Lisa J.; Beaver, L.; Vail, David M.

doi:10.1111/j.1939-1676.2004.tb00164.x

Cited by 84 publications

(67 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The total infusion time was between 3 and 6 hours. In the premedication groups, the animals were initially premedicated with prednisone (1 mg/kg PO), diphenhydramine (4 mg/kg IM), cimetidine (4 mg/kg IV), and dexamethasone Na Phos (2 mg/kg IV) according to a previous report [21], and then they received the PTX formulations by infusion as the PTX formulation treatment groups. The allergic reactions exhibited by the animals were observed and ranked according to Table 1.…”

Section: Methodsmentioning

confidence: 99%

A Novel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL: Pharmacokinetics, Biodistribution, and In Vivo Antitumor Efficacy and Safety

Wang

Zhao

et al. 2011

BioMed Research International

View full text Add to dashboard Cite

The purpose of this study was to prepare a novel paclitaxel (PTX) microemulsion containing a reduced amount of Cremophor EL (CrEL) which had similar pharmacokinetics and antitumor efficacy as the commercially available PTX injection, but a significantly reduced allergic effect due to the CrEL. The pharmacokinetics, biodistribution, in vivo antitumor activity and safety of PTX microemulsion was evaluated. The results of pharmacokinetic and distribution properties of PTX in the microemulsion were similar to those of the PTX injection. The antitumor efficacy of the PTX microemulsion in OVCRA-3 and A 549 tumor-bearing animals was similar to that of PTX injection. The PTX microemulsion did not cause haemolysis, erythrocyte agglutination or simulative reaction. The incidence and degree of allergic reactions exhibited by the PTX microemulsion group, with or without premedication, were significantly lower than those in the PTX injection group (P < .01). In conclusion, the PTX microemulsion had similar pharmacokinetics and anti-tumor efficacy to the PTX injection, but a significantly reduced allergic effect due to CrEL, indicating that the PTX microemulsion overcomes the disadvantages of the conventional PTX injection and is one way of avoiding the limitations of current injection product while providing suitable therapeutic efficacy.

show abstract

Section: Methodsmentioning

confidence: 99%

A Novel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL: Pharmacokinetics, Biodistribution, and In Vivo Antitumor Efficacy and Safety

Wang

Zhao

et al. 2011

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…However, studies evaluating responses to chemotherapy in canine HS are limited. Although there have been several reports on responses to chemotherapy using doxorubicin [14], liposomal doxorubicin [14], paclitaxel [9] and CCNU [10, 12, 13], survival time of dogs with HS has been short so far despite the use of aggressive treatments. In addition, no study has compared the prognosis in canine HS between dogs that received antitumor treatments with surgery and/or chemotherapy and those that did not receive such antitumor treatment.…”

mentioning

confidence: 99%

Clinical Characteristics and Prognostic Factors in Dogs with Histiocytic Sarcomas in Japan

et al. 2014

View full text Add to dashboard Cite

Canine histiocytic sarcoma (HS) is a rare neoplasm that originates from dendritic cells or macrophages, and there have been a number of cases experienced in Japan. To identify the characteristics and prognostic variables that determine outcome in dogs with HS in Japan, medical records of 73 dogs with HS were retrospectively analyzed. Signalment, clinical signs, complete blood count (CBC), blood chemistry profiles, treatment, response to treatment and overall survival (OS) were analyzed. Diagnosis of HS was determined histologically in 44 cases and cytologically in 29 cases. The most frequently diagnosed breeds were Flat-Coated Retrievers (n=16, odds ratio [OR] 62.0), Pembroke Welsh corgis (n=15, OR 9.7) and Bernese Mountain dogs (n=14, OR 45.0). Median survival time for all dogs in this study was 43 days. In the dogs that received no treatment or only symptomatic treatment, the median OS was 12 days (range 2–254 days) compared with that of dogs that received surgical treatment and/or chemotherapy (85 days, range 4–360 days). Univariate analysis identified anemia, thrombocytopenia, hypoalbuminemia, hypoproteinemia and not receiving antitumor treatment (chemotherapy and/or surgery) as factors significantly associated with shorter OS. Multivariate analysis confirmed that platelet counts, localized/disseminated lesional pattern and whether the dog received antitumor treatment were significantly predictive of survival.

show abstract

“…Taxol (Bristol‐Myers Squibb, Princeton, NJ), the most widely used formulation of paclitaxel, requires Cremophor EL as an excipient to allow water solubility for parenteral delivery. Taxol has shown activity in dogs with malignant tumors; however, adverse events are common with this formulation and the majority of dogs experience allergic or anaphylactic hypersensitivity reactions to the cremophor excipient despite receiving premedication with antihistamines and corticosteroids . A new formulation of paclitaxel (Paccal Vet a ) that is made water‐soluble by using a mixed micellar preparation with a surfactant based on derivatives of retinoic acid (referred to as paclitaxel [micellar] from here forward) has recently been developed .…”

mentioning

confidence: 99%

A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs

Vail

Euler

Rusk³

et al. 2012

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

Background Effective treatments for dogs with advanced stage mast cell tumors (MCT) remain a pressing need. A micellar formulation of paclitaxel (paclitaxel [micellar]) has shown promise in early-phase studies. Hypothesis/Objectives The objective was to demonstrate greater activity for paclitaxel (micellar) compared with lomustine. The null hypothesis was μp = μL (ie, proportion of responders for the paclitaxel [micellar] and lomustine groups, respectively). Animals Two hundred and fifty-two dogs with advanced stage nonresectable grade 2 or 3 MCT. Methods Prospective multicenter randomized double-blind positive-controlled clinical trial. The primary endpoint was confirmed overall response rate (CORR) at 14 weeks. A secondary endpoint, biologic observed response rate (BORR), also was calculated. Safety was assessed by the characterization and grading of adverse events (AE). Results Overall CORR (7% versus 1%; P = .048) and BORR (23% versus 10%; P = .012) were greater for paclitaxel (micellar) compared with lomustine. Paclitaxel (micellar)-treated dogs were 6.5 times more likely to have a confirmed response and 3.1 times more likely to experience a biologic observed response. The majority of AE with paclitaxel (micellar) were transient and clinically manageable. Twenty-seven dogs (33%) receiving lomustine were discontinued because of hepatopathy compared with 3 dogs (2%) receiving paclitaxel (micellar) (P < .0001; odds ratio 26.7). Conclusions and Clinical Importance Paclitaxel (micellar)’s activity and safety profile are superior to lomustine. The addition of an active and novel taxane to the veterinary armamentarium could fill a substantial need and, as its mechanism of action and AE profile do not overlap with currently available TKI, its availability could lead to effective combination protocols.

show abstract

Efficacy and Toxicity of Paclitaxel (Taxol) for the Treatment of Canine Malignant Tumors

Cited by 84 publications

References 11 publications

A Novel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL: Pharmacokinetics, Biodistribution, and In Vivo Antitumor Efficacy and Safety

A Novel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL: Pharmacokinetics, Biodistribution, and In Vivo Antitumor Efficacy and Safety

Clinical Characteristics and Prognostic Factors in Dogs with Histiocytic Sarcomas in Japan

A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs

Contact Info

Product

Resources

About